Filter By Category
Archives
Share on -
AXICABTAGENE CILOLEUCEL
Generic Name: AXICABTAGENE CILOLEUCEL
ABSTRACT -
Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T-cell immunotherapy. A patient’s T cells are engineered to express a chimeric antigen receptor containing an anti-CD19 binding domain linked to CD28 and CD3-zeta signaling domains. As a living cell therapy, it does not have a small-molecule molecular formula. The representation above shows a CAR-T cell therapy schematic.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- Dosage and administration must be determined only by certified cellular-therapy specialists at qualified treatment centers.
- Use only according to the approved local label for eligible CD19-positive hematologic malignancies.
- Treatment commonly requires lymphodepleting chemotherapy, product-specific cell dose verification, and intensive post-infusion monitoring.
- Do not substitute, repeat, or modify therapy outside specialist direction.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Cytokine release syndrome with fever, hypotension, hypoxia, tachycardia, or organ dysfunction
- Neurologic toxicity/ICANS with confusion, aphasia, tremor, seizures, encephalopathy, or cerebral edema
- Prolonged cytopenias, serious infections, hypogammaglobulinemia, or febrile neutropenia
- Fatigue, nausea, diarrhea, decreased appetite, edema, pain, or laboratory abnormalities
- Secondary malignancy, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, or severe inflammatory toxicity may occur
ALLERGIC REACTIONS -
Hypersensitivity to Axicabtagene ciloleucel or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Axicabtagene ciloleucel should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Axicabtagene ciloleucel may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Immunosuppressive therapy may affect CAR-T expansion, persistence, and toxicity management.
- Live vaccines should generally be avoided before, during, and after treatment until immune recovery.
- Concomitant chemotherapy, corticosteroids, anti-cytokine therapy, or infection prophylaxis must follow institutional protocols.
- Patients should report all medicines, vaccines, supplements, and herbal products.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Confirm identity, disease eligibility, infection status, organ function, and product-release criteria before infusion.
- Monitor closely for cytokine release syndrome and neurologic toxicity for the label-defined observation period.
- Ensure availability of emergency care, tocilizumab, seizure precautions, and infection management resources.
- Pregnancy and lactation require individualized oncology and cellular-therapy review.
WARNINGS –
- Life-threatening cytokine release syndrome and neurologic toxicity can occur.
- Serious infections, prolonged cytopenias, B-cell aplasia, and secondary malignancies require long-term follow-up.
- Use only at authorized treatment centers with trained personnel and product-specific REMS/monitoring requirements where applicable.
- Keep out of reach of children.
Share on -
. Developed by